Chest Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Landesman, S. H.
Right arrow Articles by Schiffman, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Landesman, S. H.
Right arrow Articles by Schiffman, G.

Chest, Vol 84, 433-435, Copyright © 1983 by American College of Chest Physicians

ARTICLES

Pneumococcal vaccine in elderly patients with COPD

SH Landesman, PM Smith and G Schiffman

Antibody levels to 12 serotypes of the 14 valent pneumococcal vaccine were measured in 12 patients (mean age of 70) with chronic obstructive pulmonary disease (COPD), approximately one year postvaccination and in 17 additional patients with COPD (mean age 70) who were not vaccinated. In the vaccinated group, the geometric mean antibody concentration (GMAC) 13 months postvaccination was above the presumed postvaccination minimally protective level (250 to 300 ng of antibody nitrogen per milliliter) for all serotypes except 6A and 19F. Antibody levels exceeded 700 ng for nine of 12 types. The GMAC for all 12 types was 927. In the nonvaccinated group, GMAC were slightly higher than seen with healthy younger persons (395 vs 217). It is concluded that elderly persons with COPD have adequate antibody titers for at least one year after vaccination.


This article has been cited by other articles:


Home page
 ChestHome page
J. G. Schenkein, M. H. Nahm, and M. T. Dransfield
Pneumococcal Vaccination for Patients With COPD: Current Practice and Future Directions
Chest, March 1, 2008; 133(3): 767 - 774.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
G. Sen, Q. Chen, and C. M. Snapper
Immunization of Aged Mice with a Pneumococcal Conjugate Vaccine Combined with an Unmethylated CpG-Containing Oligodeoxynucleotide Restores Defective Immunoglobulin G Antipolysaccharide Responses and Specific CD4+-T-Cell Priming to Young Adult Levels
Infect. Immun., April 1, 2006; 74(4): 2177 - 2186.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Microbiol. Rev.Home page
A. S. Artz, W. B. Ershler, and D. L. Longo
Pneumococcal Vaccination and Revaccination of Older Adults
Clin. Microbiol. Rev., April 1, 2003; 16(2): 308 - 318.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
S. Jonsson, G. Vidarsson, H. Valdimarsson, G. Schiffman, R. Schneerson, and I. Jonsdottir
Vaccination of COPD patients with a pneumococcus type 6B tetanus toxoid conjugate vaccine
Eur. Respir. J., October 1, 2002; 20(4): 813 - 818.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1983 by the American College of Chest Physicians.